Kidney Care Partners

11M U.S. workers are living with kidney disease, costing businesses $100+ billion each year. Today, @KidneyFund took this issue to Capitol Hill, elevating solutions that reduce spending and protect the nation’s workforce. Learn more: bit.ly/3R05EFH

Today is AMKD Awareness Day. People of west or central African ancestry who inherited certain variations of the APOL1 gene are at higher risk for APOL1-mediated kidney disease (AMKD), a form of genetic kidney disease. KCP supports @KidneyFund's call to action: kidneyfund.org/APOL1aware. Join the movement: bit.ly/4d0ghjc #AMKDAwarenessDay #KidneyHealth #APOL1Aware

During the hearing, the Subcommittee heard testimony from a home hemodialysis patient, leading nephrologists and researchers, and Akebia CEO/prior KCP Chair John Butler. The consensus was clear that the current system does not work for patients. bit.ly/post-hearing

KCP is pleased that House Committee on Ways & Means Health Subcommittee leaders are dedicating their time today to explore treatment improvements for individuals with kidney disease, and, importantly, at the midpoint of National Kidney Month bit.ly/4bmOLLC

@RepDelBene appreciates the bipartisan work of the Congressional Kidney Caucus, which she co-chairs with @RepCarolMiller, and raises the need for additional funding for @Kidney_X

@RepRudyYakym discusses the need to ensure patients have access to choices in all aspects of their care, including the opportunity to dialyze at home.

John Butler discusses how new approaches to TDAPA will allow a significant access improvement for drugs like DefenCath.

@RepTenney: "We have a diagnosis issue where we should have more effective integration between primary and nephrology care so we can minimize or prolong the onset of ESRD."

@RepHorsford discusses impediments and challenges to dialysis care associated with transportation problems that have jeopardized his rural constituency's access to services.

@RepBlakeMoore discusses what improvements are needed in the ESRD system for sustainability, including payment for clinical labor and adequate reimbursement that must be part of a more stable system.

@RepDannyDavis: "I am leading with @MikeKellyPA the Restore Act to help patients stay connected to prevention, education, and benefits." congress.gov/bill/119th-con…

Witnesses, including John Butler and Dr. Suzanne Watnick, speak to how the current payment system stifles innovation and how @RepCarolMiller's bill, KCAPA, will start fixing that. congress.gov/bill/119th-con…

@RepBrianFitz: "The Restore Act, which I support with @MikeKellyPA, will help ensure comfort and care continuity in their coverage for the full 30 months."

@RepCarolMiller discusses barriers to home dialysis care and her legislation in development to improve access by improving incentive structures. congress.gov/bill/119th-con…

John Butler: "When you start dialysis, you deserve the same innovations other patients get, your legislation will help improve and ensure that."

@RepCarolMiller, KCAPA sponsor, along with @RepTerriSewell, "the system has failed to sustain innovations for kidney care patients that our bill will help solve." congress.gov/bill/119th-con…

@RepGregMurphy discusses ways to improve access to kidney transplant, the only long term solution to kidney disease with witnesses. "Holy grail is to get patients off dialysis and to a transplant."

@RepGregMurphy asks about the ESRD PPS bundle's limitations on bringing new therapies into the flat bundled fee, "if that's the case, you can't access them." Fixing TDAPA "is where the solution is."

Rep. @MikeKellyPA praises patient commitments to community and family in spite of kidney failure. "My bipartisan Restore Act can really help patients continue to be positively involved in our communities." congress.gov/bill/119th-con…

John Butler: The Kidney Care Access Protection Act (KCAPA, H.R. 6214) would show innovators that resources are available to sustain new drugs and devices after the TDAPA and TPNIES periods ends." congress.gov/bill/119th-con…

Chairman @RepJasonSmith: "Medicare's bonus payments for new drugs and devices have not worked, we need to understand solutions."